British American Tobacco Plc ADR (BTI) concluded trading on Wednesday at a closing price of $52.27, with 6.75 million shares of worth about $352.82 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 47.86% during that period and on July 16, 2025 the price saw a gain of about 1.55%. Currently the company’s common shares owned by public are about 2.20B shares, out of which, 2.19B shares are available for trading.
Stock saw a price change of 6.48% in past 5 days and over the past one month there was a price change of 7.11%. Year-to-date (YTD), BTI shares are showing a performance of 60.29% which increased to 43.92% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $31.92 but also hit the highest price of $51.88 during that period. The average intraday trading volume for British American Tobacco Plc ADR shares is 6.71 million. The stock is currently trading 6.71% above its 20-day simple moving average (SMA20), while that difference is up 12.16% for SMA50 and it goes to 29.51% higher than SMA200.
British American Tobacco Plc ADR (NYSE: BTI) currently have 2.20B outstanding shares and institutions hold larger chunk of about 10.80% of that.
The stock has a current market capitalization of $114.33B and its 3Y-monthly beta is at 0.38. PE ratio of stock for trailing 12 months is 30.99, while it has posted earnings per share of $1.69 in the same period. Its PEG reads 6.66 and has Quick Ratio of 0.52 while making debt-to-equity ratio of 0.74. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for BTI, volatility over the week remained 1.64% while standing at 1.36% over the month.
Stock’s fiscal year EPS is expected to rise by 2.13% while it is estimated to increase by 5.33% in next year. EPS is likely to grow at an annualized rate of 4.65% for next 5-years, compared to annual growth of -11.33% made by the stock over the past 5-years.
On January 27, 2025, UBS Upgrade their recommendations, while on October 03, 2024, Morgan Stanley Downgrade their ratings for the stock with a price target of $33. Stock get a Neutral rating from UBS on January 23, 2024.
